Change over period: —
NSE · BALPHARMA
BAL PHARMA
-24.9% from the 52-week high · +42.3% above the low
Bal Pharma Ltd. is a holding company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Bangalore, Karnataka. The firm is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). The company is specialized in bulk actives, prescription drugs, generics and pharma intermediates. Its focused therapeutic areas are anti-diabetes, anti-histamine, anti-inflammatory, acne treatment, gastroenterology, cardiology, and dermatology. The company offers a range of APIs, which includes antihistamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment. Its finished formulation products cover dosage forms, such as tablets, capsules, syrups, suspensions, IV infusions, ophthalmic, creams and ointments. The firm offers a range of natural medicine, which includes ANARSHA, ASHWAMED, AYURFINE, AYURFINE FORTE, AYURSULIN, IMMUWIN, LIPIVED, MENOLEAP CAPSULES, MENOLEAP SYRUP, PROLIFE, and BALPRO SYRUP.
The short version. BAL PHARMA reported revenue of ₹90 crore for Sep 2026, up 21.6% from a year earlier. Net profit was ₹1 crore (up 0.0% year on year). Return on equity was 7.6% in Mar 2026. Promoter holding was 50.86% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
BAL PHARMA trades 24.9% below its 52-week high and 42.3% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹90 cr.
Sep 2026 net profit of ₹1 cr.
0.6 pts higher than a year earlier.
Revenue compounded at 0.9% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 90 | 89 | 84 | 88 | 74 | 66 | 82 | 73 |
| Net profit | 1 | 1 | 4 | 2 | 1 | 0 | 7 | 0 |
| Net margin % | 1.6 | 1.3 | 4.3 | 2.0 | 1.0 | 0.3 | 8.2 | 0.7 |
| EPS (₹) | 0.89 | 0.71 | 2.26 | 1.12 | 0.45 | 0.13 | 4.23 | 0.3 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 312 | 303 | 339 | 304 | 281 | 251 | 171 | 212 |
| Net profit | 6 | 7 | 7 | 3 | 6 | 5 | -13 | 0 |
| Net margin % | 2.0 | 2.4 | 2.2 | 0.9 | 2.0 | 1.9 | -7.5 | 0.2 |
| EPS (₹) | 3.95 | 4.53 | 4.68 | 1.67 | 3.78 | 3.2 | -9.1 | 0.27 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 7.6% in Mar 2026; debt to equity is 1.94.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 7.6 | 9.3 | 10.7 | 4.1 |
| Return on capital % | 18.0 | 18.9 | 20.9 | 16.3 |
| EBITDA margin % | 10.8 | 10.4 | 10.1 | 8.5 |
| Net margin % | 2.0 | 2.4 | 2.2 | 0.9 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 0.9% | 4.5% |
| Profit CAGR | 33.9% | 5.8% |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Up 0.14 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 50.86 | 50.86 | 50.86 | 50.86 | 50.86 | 50.86 | 50.86 | 50.86 | 0.0 |
| FII | 0.14 | 0.14 | 0.15 | 0.22 | 0.14 | 0.14 | 0.15 | 0.28 | +0.14 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 49.0 | 49.0 | 48.99 | 48.92 | 49.01 | 49.01 | 48.99 | 48.87 | -0.13 |
Mutual fund holdings · Oct 2026
0 schemes hold this stock
0 the month before.
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for BAL PHARMA are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about BAL PHARMA
What is the BAL PHARMA share price?
BAL PHARMA (BALPHARMA) last closed at ₹84.61, down 1.62% on the day. Its 52-week range is ₹60.42 to ₹114.45.
What is the market cap of BAL PHARMA?
BAL PHARMA has a market capitalisation of about ₹135 crore. Its price-to-earnings ratio is 17.0.
How are BAL PHARMA's latest results?
BAL PHARMA reported revenue of ₹90 crore for Sep 2026, up 21.6% from a year earlier. Net profit was ₹1 crore (up 0.0% year on year). Return on equity was 7.6% in Mar 2026. Promoter holding was 50.86% in Sep 2026, up 0.00 points over 8 quarters.
Who owns BAL PHARMA?
As of Sep 2026, shareholding was: Promoter 50.86%, FII 0.28%, Public 48.87%.
How many mutual funds hold BAL PHARMA?
0 mutual fund schemes held BAL PHARMA in October 2026. That compares with 0 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 18 Sep 2025 · Dividend - Rs. 1.2
- 17 Sep 2024 · Final Dividend - Rs. 1.2
- 18 Sep 2023 · Final Dividend - Rs. 1
- 13 Sep 2022 · Final Dividend - Rs. 1
- 16 Sep 2021 · Final Dividend - Rs. 1
- 17 Sep 2019 · Final Dividend - Rs. 1
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.